An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) With Heterozygous Familial Hypercholesterolemia
Latest Information Update: 04 Mar 2025
Price :
$35 *
At a glance
- Drugs Bempedoic acid (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Acronyms CLEAR Path 1
- Sponsors Esperion Therapeutics
- 26 Feb 2025 Planned End Date changed from 24 May 2024 to 1 Aug 2025.
- 26 Feb 2025 Planned primary completion date changed from 24 Mar 2024 to 1 Jun 2025.
- 29 Sep 2022 New trial record